STUDY LOOKS AT SAFETY OF SHRINKING BRAIN-CANCER TUMOURS USING MIXTURE OF THC, CBD AND CHEMO-THERAPY
Tilray is collaborating with The Spanish Group for Neuro-oncology in an open-label clinical trial involving 30 patients with newly diagnosed glioblastoma, an aggressive form of brain cancer.
+Slated to start in July 2019, according to clinical-trial records updated on May 31, 2019.
+Primary completion expected by June 2020.
+Builds on previous research that showed a clear anti-tumour effect when THC, CBD, TMZ and radiotherapy were combined in pre-clinical glioma models.
+Cannabinoids have been shown to destroy tumour cells by “activating” receptors in the brain and in the immune system, in experimental research.
+1:1 ratio of THC and CBD will be involved in the open-label clinical trial.
The Spanish Group for Neuro-oncology (Grupo Español de Investigación en Neurooncologíais) is sponsoring the research.